Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Herbalife

This article was originally published in The Tan Sheet

Executive Summary

Tender offer by Chairman and CEO Mark Hughes for the company's Class A and Class B stock is terminated, as is the buy-out agreement Hughes arranged between his MH Millenium Acquisition Corp. and Herbalife. In an April 10 statement, Hughes attributed the transactions' termination to "extremely adverse conditions in the credit markets," but said the firm will continue to "maximize shareholder value by expanding and improving the Herbalife business worldwide." Hughes had announced his intention to buy all the company's remaining shares and take it private on Sept. 13, stating Herbalife had "not been rewarded in the public equity markets" (1"The Tan Sheet" Sept. 20, 1999, p. 15)

You may also be interested in...



Herbalife Management Conflicts Of Interest Questioned By Investment Groups

Herbalife execs' dual responsibilities as directors of the firm and trustees in the estate of its founder could produce "serious conflicts of interest," two investment groups charge in a July 24 letter to the board.

Herbalife Management Conflicts Of Interest Questioned By Investment Groups

Herbalife execs' dual responsibilities as directors of the firm and trustees in the estate of its founder could produce "serious conflicts of interest," two investment groups charge in a July 24 letter to the board.

Herbalife Management Conflicts Of Interest Questioned By Investment Groups

Herbalife execs' dual responsibilities as directors of the firm and trustees in the estate of its founder could produce "serious conflicts of interest," two investment groups charge in a July 24 letter to the board.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel